Drugs
Researchers in the United States evaluated the effectiveness of vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in pneumonia, finding that even high doses of the antibiotic failed to achieve significant bactericidal activity against the bacteria. The study, published in Antimicrobial Agents and Chemotherapy, simulated various vancomycin exposures using an in vitro
Drugs
The REPLACE Registry, a large prospective study, has provided significant insights into the factors influencing infection rates in device replacement procedures. Analysis of 1,031 patients undergoing elective replacement of their implanted cardiac rhythm management (CRM) device revealed two key factors contributing to infection rates: preoperative skin preparation and post-operative
Drugs
Recent research published in the British Journal of Pharmacology has found that the efficacy of oxaliplatin, a platinum-based compound effective in treating colorectal cancer, can be impaired by the presence of the cetuximab monoclonal antibody. The study, conducted by L. Dahan and colleagues at Aix-Marseille University, evaluated the effect of
Drugs
Scientists in the United States have been studying the role of P-glycoprotein (P-gp), an efflux transporter, in various disorders, including multidrug-resistant cancer and medication-refractory epilepsy. Researchers at the National Institutes of Health (NIH) have developed radiolabeled P-gp substrates to image P-gp function using single-photon emission computed tomography (SPECT) and positron
Drugs
Scientists in Beijing, People's Republic of China, have developed a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus, specifically the Ad5-LFA-3/IgG(1) gene therapy treatment for psoriasis. The method showed good specificity, sensitivity, and reproducibility over a wide dynamic range of concentrations, providing valuable
Drugs
Researchers at Mukogawa Women's University in Nishinomiya, Japan, have investigated the cytotoxic mechanism of Vitamin K-3 (VK3) on breast cancer cells. Their study revealed that VK3 causes DNA fragmentation, mitochondrial dysfunction, and activation of caspase-7 and -9, leading to apoptosis in MCF-7 cells. The researchers concluded that VK3-induced
Drugs
Researchers in Larisa, Greece, conducted a meta-analysis to investigate the relationship between MTHFR gene polymorphisms and response to fluorouracil-based chemotherapy in patients with colorectal cancer. The analysis included ten studies relating MTHFR C677T and six studies relating MTHFR A1298C to the response to chemotherapy. The study found that for both
Drugs
Researchers in the United States have made a groundbreaking discovery in the fight against metastatic prostate cancer. A new study published in the journal Oncogene has found that a novel proteasome inhibitor, NPI-0052, has the potential to inhibit the spread of cancer cells by targeting a key protein involved in
Drugs
Researchers at the University of Heidelberg in Germany have made a significant discovery about the epigenetic regulation of genes in gliomas, a type of brain cancer. The study found that the death receptor 4 (DR4) gene is frequently methylated in human astrocytic gliomas, leading to resistance to tumor necrosis factor-related
Drugs
Renal cell carcinoma (RCC) is the eighth most commonly diagnosed malignancy in the United States, with localized disease found in about 55% of patients. Standard therapy has undergone significant change, with cytokines like interferon alfa and aldesleukin largely displaced by molecularly targeted agents such as sorafenib tosylate, sunitinib malate, and
Drugs
Seattle Genetics, a clinical stage biotechnology company focused on cancer and autoimmune disease therapies, announced that its management team will present at the Fourth Annual JMP Securities Healthcare Focus Conference on October 5, 2009. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under
Drugs
Researchers at the University of Buenos Aires, Argentina, have identified a novel approach to targeting cancer cells by leveraging the microenvironment's increased reactive oxygen species (ROS) production. By developing a chimeric promoter that responds to ROS fluctuations, they created a gene therapy that selectively inhibits cancer cell growth
